about
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemiaEfficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemiaPrognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.Oncogenic retroviruses in animals and humans.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsThe MLL recombinome of acute leukemias in 2013.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialMesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutationsCD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapyPrognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.The MLL recombinome of acute leukemias in 2017.Evidence-based RT-PCR methods for the detection of the 8 most common MLL aberrations in acute leukemias.Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.A BACH2-BCL2L1 fusion gene resulting from a t(6;20)(q15;q11.2) chromosomal translocation in the lymphoma cell line BLUE-1.BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype.Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma.No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasmsLong-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.Molecular characterization and clinical course of MLL-ACTN4 rearrangement in therapy-related hematologic malignancies.Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation.Involvement of the MLL gene in adult T-lymphoblastic leukemia.New insights to the MLL recombinome of acute leukemias.Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy.Insertional polymorphisms of endogenous HERV-K113 and HERV-K115 retroviruses in breast cancer patients and age-matched controls.Flow cytometric maturity score as a novel prognostic parameter in patients with acute myeloid leukemia.BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.EZH2: a pleiotropic protein.Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes.
P50
Q30365752-356B0162-D8D4-4C5C-871B-2C5017ECBE2EQ30836557-AD36BE07-E0B1-4A8F-ADDF-B05D49E04983Q33632230-534642DE-DAA1-4015-9D31-033383E9FEDBQ33886181-0BD7A893-AB30-4F35-940E-B8EAD7C2728AQ34464952-DFFD068F-9779-4F28-B03F-6D3B5A951E9BQ34566158-94C15F29-55B3-4BFF-9753-B20372A07CD5Q34651113-C9380A92-6AF9-4B44-99FE-2C0BA660BC98Q34737471-10B87AC0-F080-46C7-A0AF-6882C61BDE44Q35553350-9A874070-BF6D-4901-8AAC-A67D0573A965Q35723764-1B039546-183E-445F-BCF6-DFE918190F44Q37082729-4EA3544F-4E20-4157-82AB-04E62861AE3FQ37369925-F0A8DDEB-387D-4826-9122-8B3159B172A1Q38681972-AD14DC25-071C-47FB-A070-1D875BD23995Q38928421-C4AD084F-CCFD-4A3B-BEB5-8B1DAA13C762Q38943340-A2BA5DFB-0138-42A1-B9F3-926F2400C1A1Q39574938-72295F10-C039-4AF4-992F-39BBA08427A7Q39685853-2C8B670E-21EA-4384-A776-E2D90B5C2867Q39691088-2EB0586C-7BDE-48A6-880E-62856835366AQ40280616-EA1F3D92-5FC2-41A6-BED2-738E70A9D582Q40571894-A82C6A4A-DC0C-4CE6-B7DE-E80DAE610400Q41134120-8BA8B759-F63C-47FA-B4F6-7A29BCD4A04FQ42154771-3DF58874-E604-43DE-BDF7-FECBBA1124DCQ42361917-2C45E554-3C7F-43C7-93C0-3A829D0A3BFEQ42368324-452AE7EC-054D-4C4F-8953-A45FDA1A0593Q42385059-241982DC-E6EA-4802-9896-856ECBB4E1EDQ42632052-6157FDD6-1416-4249-B244-3B7935FB48CCQ42965600-14053E62-1D37-4BB4-82E2-F95C3DC2F710Q44647936-BEA1CD09-4666-4C27-AD65-A8C75A3AC868Q44849510-8A0A7D16-1F1F-42D2-AB1C-A002DDBFE440Q44945193-20C3C1EE-D6B7-436B-8263-24466EB7E9FCQ46341511-2559786F-2395-41F7-8D67-8101E9B6FD48Q46416550-AA218838-0588-424F-9D86-8FCCCB634FEBQ47304146-B42C4E89-AC84-4A9B-B354-1D121DE769E3Q47829263-1680611A-BD1B-4FD4-AD55-01E15C7C50F9Q47834547-410043E8-2931-4110-B0FD-296191BE3845Q47838758-8790471B-2798-4FE2-A412-509D31F81C26Q48097499-83EBCCC8-6A13-406A-896F-948D678E5C56Q48104819-69A544C5-FDDA-4179-B89E-3D2F43905AC4Q48143766-795B3656-45AB-4827-BF31-C33B8DC77A62Q48423151-6B5FD5D6-635E-4393-81A8-FE943A142528
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Thomas Burmeister
@ast
Thomas Burmeister
@en
Thomas Burmeister
@es
Thomas Burmeister
@nl
Thomas Burmeister
@sl
type
label
Thomas Burmeister
@ast
Thomas Burmeister
@en
Thomas Burmeister
@es
Thomas Burmeister
@nl
Thomas Burmeister
@sl
prefLabel
Thomas Burmeister
@ast
Thomas Burmeister
@en
Thomas Burmeister
@es
Thomas Burmeister
@nl
Thomas Burmeister
@sl
P214
P106
P1153
6602383792
P21
P214
P31
P496
0000-0003-4843-2876
P734
P735
P7859
viaf-313237764